Prefer midcap pharma stocks on correction: Kunj Bansal

Kunj Bansal of Centrum Wealth Management is of the view that one may prefer midcap pharma stocks on correction.

Kunj Bansal of Centrum Wealth Management told CNBC-TV18, "Any good quality pharma stock especially from midcap if it corrects, it is certainly a good buying opportunity given their valuations and the sharp run-up that we saw in recent past."

"Even over the medium and longer term the sector is likely to give a slower return but will continue to give good returns over a medium term. They may not be sharp movers in the short term, that is certainly true," he said.